After Prometheus Loss, High Court Eyes Cancer Gene Patent
Now that the U.S. Supreme Court has invalidated Prometheus Laboratories Inc.'s blood testing method patents, the life sciences patent spotlight shifts to a case over the validity of breast cancer genes...To view the full article, register now.
Already a subscriber? Click here to view full article